Log In
Print
BCIQ
Print
Print this Print this
 

Esbriet, Pirfenex, pirfenidone (Pirespa) (S-7701)

  Manage Alerts
Collapse Summary General Information
Company InterMune Inc.
DescriptionSmall molecule inhibitor of proinflammatory cytokines and pro-fibrotic cytokines that targets p38 MAPK
Molecular Target Tumor necrosis factor (TNF) alpha ; Transforming growth factor (TGF) beta 1 (TGFB1)
Mechanism of ActionMAP kinase (p38) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationPulmonary fibrosis
Indication DetailsTreat idiopathic pulmonary fibrosis (IPF); Treat mild to moderate idiopathic pulmonary fibrosis (IPF)
Regulatory Designation

U.S. - Fast Track (Treat idiopathic pulmonary fibrosis (IPF));
U.S. - Orphan Drug (Treat mild to moderate idiopathic pulmonary fibrosis (IPF));
U.S. - Orphan Drug (Treat idiopathic pulmonary fibrosis (IPF));
U.S. - Priority Review (Treat idiopathic pulmonary fibrosis (IPF));
EU - Named Patient Program (Treat idiopathic pulmonary fibrosis (IPF));
EU - Orphan Drug (Treat idiopathic pulmonary fibrosis (IPF));
EU - Orphan Drug (Treat mild to moderate idiopathic pulmonary fibrosis (IPF))

Partner

Cipla Ltd.; GNI Group Ltd.; Ildong Pharmaceutical Co. Ltd.; Shionogi & Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today